Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof

US5256642A · kind A · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• The Brigham and Women's Hospital, Inc. · US
• T Cell Sciences, Inc. · US

Inventors

• Douglas T. Fearon · Baltimore, US
• Lloyd B. Klickstein · Brookline, US
• Winnie W. Wong · Newton, US
• Gerald R. Carson · Belmont, US
• Michael F. Concino · Bolton, US
• Stephen H. Ip · Sudbury, US
• Savvas C. Makrides · Bedford, US
• Henry C. Marsh, Jr. · Reading, US

Key dates

• Filing date: Sep 24, 1990
• Grant date: Oct 26, 1993
• Expiry date: Sep 24, 2010

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.